FDA Approvals - Amarillo Biosciences Submits Investigational New Drug Application to Test Oral
Amarillo Biosciences Submits Investigational New Drug Application to Test Oral Interferon in Idiopathic Pulmonary (Market Wire via Yahoo! Finance)
Amarillo Biosciences, Inc. today announced that it submitted an Investigational New Drug Application to the FDA to begin a study of orally delivered interferon alpha in 60 patients with idiopathic pulmonary fibrosis. These IPF patients will be enrolled from approximately six clinical sites in the US. The patients will be given interferon or placebo for four weeks to assess the effect of
Amarillo Biosciences Submits Investigational New Drug Application to Test Oral Interferon in Idiopathic Pulmonary (SYS-CON Media)
Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR)today announced that it submitted an Investigational New Drug (IND)Application to the FDA to begin a study of orally delivered interferonalpha in 60 patients with idiopathic pulmonary fibrosis (IPF). These IPFpatients will be enrolled from approximately six clinical sites in the US.The patients will be given interferon or placebo for four weeks to